

Musculoskeletal Development and Physical Therapy Approaches in Children with Chromosome 21 Abnormalities

Matteo Bianchi*

Department of Pediatric Rehabilitation, Sapienza University of Rome, Rome, Italy

DESCRIPTION

Musculoskeletal development plays a critical role in motor function, mobility, and overall independence in children with chromosome 21 abnormalities. Hypotonia, ligamentous laxity, delayed motor milestones, and postural instability contribute to challenges in gross and fine motor skills. Early assessment and structured physical therapy interventions are essential to optimize strength, coordination, and functional mobility, supporting daily living activities and long-term quality of life [1].

Hypotonia, or reduced muscle tone, is a hallmark characteristic affecting movement efficiency, stability, and endurance. Children with low muscle tone often exhibit delayed achievement of motor milestones such as sitting, crawling, and walking. This delay can impact exploration, social interaction, and cognitive development, emphasizing the importance of early evaluation and therapeutic support [2]. Ligamentous laxity increases joint flexibility but reduces stability. While some flexibility may appear advantageous, excessive laxity can compromise alignment, increase the risk of injury, and affect gait patterns. Targeted physical therapy interventions aim to strengthen supporting musculature, improve joint stability, and promote safe movement strategies [3].

Gross motor development, including balance, walking, running, and climbing, is often slower compared to typically developing peers. Structured therapy programs incorporate exercises for core strength, postural control, and coordination. Play-based activities, obstacle courses, and adaptive sports provide motivating environments for practicing skills while addressing strength and stability deficits [4]. Fine motor skills are supported indirectly through musculoskeletal development. Enhanced upper limb strength, wrist stability, and shoulder control facilitate hand coordination, object manipulation, and self-care tasks. Physical therapy programs that integrate gross motor and fine motor exercises improve functional independence and confidence [5].

Early intervention is crucial. Initiating therapy in infancy or toddlerhood takes advantage of neuroplasticity and

developmental windows. Consistent therapy sessions, caregiver engagement, and home exercise programs accelerate skill acquisition and promote generalization of learned movements to daily activities. Postural control and balance are central targets of intervention. Exercises such as sitting on therapy balls, reaching activities, and dynamic weight-shifting improve proprioception and core stability. Enhanced postural control supports safer mobility, reduces fall risk, and enables participation in school and recreational activities [6].

Adaptive equipment supports musculoskeletal development when necessary. Orthoses, supportive seating, and mobility aids facilitate alignment, prevent deformities, and allow children to engage in therapeutic and daily activities effectively. Physical therapists assess the need for such devices on an individualized basis and provide training for both children and caregivers. Integration into educational and recreational settings further supports motor development. Schools and community programs can provide inclusive physical activity opportunities, structured play, and peer interaction. Therapists collaborate with educators to modify activities, ensuring safety while promoting skill acquisition and social participation [7-9]. Musculoskeletal assessments, including range of motion, strength testing, and gait analysis, guide intervention planning. Regular reassessment allows therapists to adjust exercises, monitor improvements, and address emerging challenges, such as scoliosis, hip instability, or delayed coordination.

Long-term outcomes of early and structured physical therapy include improved independence in mobility, enhanced participation in daily life and recreational activities, reduced risk of musculoskeletal complications, and better overall physical fitness. Children who receive consistent intervention demonstrate increased confidence and a higher quality of life [10]. Emerging research explores optimal strategies for musculoskeletal development, including neuromuscular training, aquatic therapy, and task-oriented interventions. Evidence suggests that individualized programs combining strength, coordination, and functional activities yield the most significant improvements in motor function.

Correspondence to: Matteo Bianchi, Department of Pediatric Rehabilitation, Sapienza University of Rome, Rome, Italy, E-mail: matteo.bianchi@pediatrehabmail.org

Received: 02-Jun-2025, Manuscript No. JDSCA-25-41052; **Editor assigned:** 04-Jun-2025, PreQC No. JDSCA-25-41052 (PQ); **Reviewed:** 18-Jun-2025, QC No. JDSCA-25-41052; **Revised:** 25-Jun-2025, Manuscript No. JDSCA-25-41052 (R); **Published:** 02-Jul-2025, DOI: 10.35248/2472-1115.25.11.297

Citation: Bianchi M (2025). Musculoskeletal Development and Physical Therapy Approaches in Children with Chromosome 21 Abnormalities. J Down Syndr Chr Abnorm. 11:297.

Copyright: © 2025 Bianchi M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

CONCLUSION

Musculoskeletal development is a foundational aspect of motor, functional, and social outcomes in children with chromosome 21 abnormalities. Hypotonia, ligamentous laxity, and delayed milestones necessitate early assessment, individualized physical therapy, caregiver involvement, adaptive equipment, and integration into daily life and educational activities. By supporting musculoskeletal growth and motor function, children achieve improved mobility, independence, and participation, laying the foundation for a healthier and more active childhood and adolescence.

REFERENCES

1. Baek KH, Zaslavsky A, Lynch RC, Britt C, Okada Y, Siarey RJ, et al. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. *Nature*. 2009;459:1126-1130.
2. Bakshi R, Zaidi SK, Pande S, Hassan MQ, Young DW, Montecino M, et al. The leukemogenic t(8;21) fusion protein AML1-ETO controls rRNA genes and associates with nucleolar-organizing regions at mitotic chromosomes. *J Cell Sci*. 2008;121:3981-3990.
3. Béri-Dexheimer M, Latger-Cannard V, Philippe C, Bonnet C, Chambon P, Roth V, et al. Clinical phenotype of germline RUNX1 haploinsufficiency: From point mutations to large genomic deletions. *Eur J Hum Genet*. 2008;16:1014-1018.
4. Carmichael CL, Majewski IJ, Alexander WS, Metcalf D, Hilton DJ, Hewitt CA, et al. Hematopoietic defects in the Ts1Cje mouse model of Down syndrome. *Blood*. 2009;113:1929-1937.
5. Forestier E, Izraeli S, Beverloo B, Haas O, Pession A, Michalova K, et al. Cytogenetic features of acute lymphoblastic and myeloid leukemias in pediatric patients with Down syndrome: An iBFM-SG study. *Blood*. 2008;111:1575-1583.
6. Gropp A, Winking H, Herbst EW, Claussen CP. Murine trisomy: Developmental profiles of the embryo, and isolation of trisomic cellular systems. *J Exp Zool*. 1983;228:253-269.
7. Hasle H. Pattern of malignant disorders in individuals with Down's syndrome. *Lancet Oncol*. 2001;2:429-436.
8. Izraeli S, Rainis L, Hertzberg L, Smootha G, Birger Y. Trisomy of chromosome 21 in leukemogenesis. *Blood Cells Mol Dis*. 2007;39:156-159.
9. Klusmann JH, Creutzig U, Zimmermann M, Dworzak M, Jorch N, Langebrake C, et al. Treatment and prognostic impact of transient leukemia in neonates with Down syndrome. *Blood*. 2008;111:2991-2998.
10. Lejeune J, Gautier M, Turpin R. Les chromosomes humains en culture de tissus. *C R Acad Sci*. 1959;248:602-603.